

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Rasappa G. Arumugham et al.

Application No.: 10/583,503

Filed: November 17, 2006

For: A-BETA IMMUNOGENIC  
PEPTIDE CARRIER CONJUGATES  
AND METHODS OF PRODUCING  
SAME

Customer No.: 00826

Confirmation No.: 4013

Examiner: Satyanarayan R. Gubibande

Art Unit: 1654

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

---

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

The references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In compliance with the requirements of 37 CFR §1.98(a)(2), copies of the references are submitted herewith.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)


The undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.704(d)

The undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

This IDS is being filed before the issuance of a Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 16-0605. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Lance A. Termes  
Reg. No. 43,184

Customer No. 00826  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel: Silicon Valley Office (650) 838-2000  
Fax: Charlotte Office (704) 444-1111  
LAT/jcf  
LEGAL02/32764244v1